PULIKE(SH:603566)2023-04-25 16:00Financial Performance - The company's operating revenue for 2022 reached RMB 1.228 billion, an increase of 11.78% compared to the previous year[21]. - The net profit attributable to shareholders decreased by 28.68% to RMB 174.11 million in 2022[21]. - The net profit after deducting non-recurring gains and losses was RMB 154.24 million, down 16.57% year-on-year[21]. - The cash flow from operating activities increased by 9.69% to RMB 233.13 million[21]. - The total assets at the end of 2022 were RMB 3.387 billion, a 56.19% increase from the previous year[21]. - The basic earnings per share decreased by 30.77% to RMB 0.54[22]. - The weighted average return on equity dropped by 5.70 percentage points to 8.42%[22]. - The company achieved operating revenue of CNY 1,228,016,476.46, an increase of 11.78% compared to the previous year[54]. - Operating costs rose to CNY 457,340,033.52, reflecting a 20.37% increase due to higher product sales and increased depreciation from fixed assets[54][55]. - The net cash flow from operating activities was CNY 233,129,092.10, up 9.69% year-on-year, driven by increased product sales[54]. - The total cash dividend amount for the year is CNY 62,928,340, which represents 25.78% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 244,137,406.56[152]. Research and Development - The company invested CNY 90.46 million in R&D, accounting for 7.37% of its revenue[31]. - The company obtained 4 new veterinary drug registration certificates and 4 clinical trial approvals during the reporting period[31]. - The company is developing a vaccine for African swine fever and has submitted an emergency evaluation application[32]. - The company has established a multi-valent vaccine research platform and is building an mRNA vaccine development platform[33]. - The company achieved nearly 40% growth in export revenue from high pathogenic avian influenza vaccines compared to the previous year[36]. - The company has several ongoing R&D projects, including a vaccine for African swine fever and a trivalent inactivated vaccine for avian influenza, currently in preclinical and clinical trial phases[80]. - The company launched a new inactivated vaccine for rabies (r3G strain) with an approval number valid until February 16, 2027[82]. - The company is focusing on innovative product development, particularly in gene-engineered vaccines and multi-valent vaccines, to meet market demands[79]. - The company’s R&D investment in the African swine fever vaccine project was ¥12.66 million, marking a 142.81% increase compared to the previous year[88]. Market Strategy and Operations - The company is expanding its product lines in pet vaccines and drugs, with several products receiving registration and approval[34]. - The company is actively coordinating resources to build a new sales department for ruminants and waterfowl[35]. - The company is enhancing its marketing management system to improve organizational efficiency and operational vitality[30]. - The company established a sales network covering 30 provinces, enhancing strategic partnerships with direct customers and distributors[51]. - Direct sales accounted for 62.06% of total revenue in 2022, up from 54.81% in 2021, while distributor sales decreased to 37.09% from 44.44%[91]. - The company is committed to innovation in vaccines and pharmaceuticals, focusing on health farming and food safety[51]. - The company is focusing on expanding its market presence through the development of innovative vaccines and treatments for livestock and pets[80]. - The company is committed to an international development strategy, promoting overseas market expansion and technical cooperation[106]. Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company has established a governance structure that ensures independent operation of the board and management, with 12 board meetings held during the reporting period[121]. - The company maintains a high level of transparency in information disclosure, ensuring compliance with legal requirements and timely communication with stakeholders[122]. - The company has implemented measures to ensure the independence of its assets, personnel, and operations, with no interference from controlling shareholders in decision-making processes[123]. - The company has established specialized committees under the board, including the Audit Committee and the Strategic Committee, to enhance governance[137]. - There were no penalties from securities regulatory agencies in the past three years, indicating compliance and good standing[133]. Environmental and Social Responsibility - The company invested CNY 5.9233 million in environmental protection during the reporting period[159]. - The company has implemented effective pollution prevention facilities, ensuring that all pollution control equipment operates well and meets regulatory standards for emissions[162]. - The company emphasizes the protection of employee rights and has signed labor contracts, ensuring insurance and provident fund contributions[169]. - The company is committed to sustainable development while actively participating in social welfare initiatives[171]. - The company has established a comprehensive environmental monitoring plan, ensuring compliance with national environmental regulations and standards[165]. Shareholder Engagement and Compensation - The company has established a three-year shareholder return plan (2021-2023) to ensure stable and sustainable returns for investors[147]. - The total remuneration for all directors, supervisors, and senior management personnel amounted to 18.1843 million yuan[132]. - The remuneration policy for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[132]. - The company held its first extraordinary general meeting of shareholders on April 11, 2023, electing a new board of directors and supervisory board members[126]. - The report highlights the importance of shareholder engagement and transparency in executive compensation practices[124].